Skip to content

Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement

Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03121053
Acronym
PANTER
Enrollment
200
Registered
2017-04-19
Start date
2016-10-31
Completion date
2019-01-31
Last updated
2017-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Aortic Valve Disease, Chronic Kidney Disease, Contrast Induced Nephropathy

Keywords

transcatheter aortic valve implantation, transcatheter aortic valve replacement

Brief summary

Chronic kidney disease (CKD) and (subsequent) acute kidney injury are frequent in patients undergoing transcatheter aortic valve implantation (TAVI). Moreover, these patients are easily hypervolemic and susceptible for cardiac decompensation. Prevention of contrast induced nephropathy (CIN) has not yet been studied in these patients, and evidence on different strategies is urgently needed. The objective of this study is to evaluate the efficacy of 250ml 1.4% sodium bicarbonate versus hypotone saline (0.65% sodiumchloride) hydration prior to TAVI in patients with CKD to prevent CIN.

Interventions

DRUGsodium bicarbonate
DRUGhypotone saline

Sponsors

St. Antonius Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Patient has provided written informed consent. 2. Patient is undergoing TAVI. 3. Patient has an estimated GFR \<60ml/min/1.73m2.

Exclusion criteria

1. Patient has end-stage kidney disease requiring dialysis. 2. Emergent TAVI (planned before next working day). 3. Recent exposure to radiographic contrast agents (within 2 days prior to the TAVI). 4. Allergy to contrast agent. 5. Planned administration of dopamine, mannitol, fenoldopam or N-acetylcysteine during the intended time of the study. 6. Need for continuous hydration therapy (e.g. sepsis). 7. Multiple myeloma. 8. Contra-indication to sodium bicarbonate.

Design outcomes

Primary

MeasureTime frameDescription
Contrast induced nephropathyDay 3CIN is defined as an increase in Scr \>0.5 mg/dL or 25% within 72 hours
Acute heart failure due to volume expansionDay 3

Secondary

MeasureTime frameDescription
Composite of CIN or acute heart failureDay 3
Maximal relative change in serum creatinineDay 3
Acute kidney injuryDay 3According to AKIN classification
Need for dialysisDay 30
Need for blood transfusionsDay 3 and Day 30
Number of blood transfusionsDay 3 and Day 30
Length of hospital stayDay 30
Recovery of renal function in CIN patientsDay 30Recovery defined as an increase in serum creatinine \<25% or \<44 μmol/L (0.5 mg/dL) measured at 1 month post-TAVI compared with baseline

Countries

Netherlands

Contacts

Primary ContactVincent Nijenhuis, MD
v.nijenhuis@antoniusziekenhuis.nl+31 65 274 2486

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026